Table 2.

Effect of First-Line Chemotherapy on EGFR Mutation Status Before and After Treatment in Plasma Samples From Patients With Stages IIIb to IV NSCLC (n = 264)

Prechemotherapy	Postchemotherapy				Total
	Wild Type		Mutated
	No.	%	No.	%	No.	%
Wild type	149	56.4	24	9.1	173	65.5
Mutated	54	20.5	37	14.0	91	34.5
Total	203	76.9	61	23.1	264	100.0

NOTE. P < .001 (McNemar test).

Abbreviation: NSCLC, non–small-cell lung cancer.